Leaders in Partnering, M&A Deals and Strategic Alliances
What We Do
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 29 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts from innovators to large pharma makes us uniquely placed to support business in all aspects of deal making and strategic planning.
PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific.
More about us
Our Services
M&A
Licensing
Fundraising
- M&A (divestments, mergers, acquisitions, and strategic transactions)
- Licensing (in and out licensing)
- Fundraising
- Strategy (commercialisation, deal strategy, due diligence, market entry)
- Valuation and Positioning (licensing, M&A, fundraising, and expert testimonies)
Upcoming Webinar
How is M&A Shifting the Pharma Manufacturing Landscape?
22nd June, 2021 4pm CET / 10am EST / 3PM BST
Innovative manufacturing technologies are creating fresh deal-making opportunities for Pharma Manufacturers and CDMOs across both small and large molecule sectors, which are in turn transforming the pharma manufacturing landscape.
This webinar will examine the trends and developments driving deal-making in the current market.
PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH
Oxford, UK, 03 March 2021 PharmaVentures is pleased to announce it acted as exclusive M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH. ERA Consulting is a leading strategic...
For the Latest Industry Information
Our Track Record
We conducted a detailed assessment of the market opportunities, technology risks and developments, launch and marketing costs via scenarios of “go-it-alone”, “outright sale”, “out-licensing for royalties” as well as “out-licensing with co-promotion”. The value generated was modelled and the scenarios were prioritised. Partnering and deal strategies were developed for the selected optimal strategy and incorporated into a business plan.
PharmaVentures developed a customised search strategy based on the specific requirements of the client, which involved a systemic country by country identification of candidates with the correct therapeutic indications, combined with their commercial potential and availability for the territories of interest.
PharmaVentures conducted a compound valuation (bottom-up and benchmarking using PharmaDeals Agreements® data) providing the basis for future negotiations. We also carried out a thorough company screening and evaluation assessment to identify and prioritise potential licensees. Following the screening, within the space of a month our transaction team approached all the target companies with a carefully constructed value proposition using a non-confidential information package.
Vaccines, patents and supply
by Dr Fintan Walton, CEO, PharmaVentures. In my experience, quick fix solutions to complex issues are usually founded on a total misunderstanding of the problem causing the issue at hand, and if...
Our Clients
What Our Clients Say
“I feel I made an excellent choice in PharmaVentures to serve as my exclusive advisors for the sale of the Company. They have a comprehensive understanding of our business and helped me identify the ideal partner that shared our strategic vision…I truly value the professional advice and the expert guidance made through every step of the process which enabled us to close the transaction to the satisfaction of all stakeholders.”